Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Kangtai Starts Mid-Stage Trial of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recombinant Covid-19 Vaccine (Adenovirus Vector) Licensed for Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Shenzhen Kangtai Biological Products

    Menu

    Shenzhen Kangtai Biological Products

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Shenzhen Kangtai Biological Products

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Recombinant Covid-19 Vaccine (Adenovirus Vector) Licensed for Manufacturing

              Details:

              Recombinant COVID-19 Vaccine(Adenovirus Vector) jointly developed by AstraZeneca and University of Oxford has been approved for use in 185 countries. The vaccine with acodenamed AZD1222, is sold under the brand names Covishield and Vaxzevria.

              Lead Product(s): AZD1222

              Therapeutic Area: Infections and Infectious Diseases Product Name: Covishield

              Highest Development Status: Approved Product Type: Vaccine

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Shenzhen Kangtai Biological Products

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              China's Kangtai Starts Mid-Stage Trial of its COVID-19 Vaccine Candidate

              Details:

              Kangtai’s candidate is among more than 10 potential vaccines Chinese scientists have brought into various phases of clinical trials in efforts to counter the virus that has killed more than 1.1 million people globally.

              Lead Product(s): COVID-19 vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY